

News Release

December 22, 2021

Tianjin Tanabe and Suzuken (Shenzhen) join hands to promote TENELIA in China

Tianjin Tanabe Seiyaku Co., Ltd. (hereinafter, Tianjin Tanabe; Head Office: Tianjin, China) and Suzuken (Shenzhen) Pharmaceutical Co., Ltd. (hereinafter, Suzuken (Shenzhen); Head Office: Shenzhen, China; Chairman : Mao Mingchuan) signed an exclusive strategic agreement to promote the type 2 diabetes treatment drug TENELIA (Teneligliptin) in mainland China on December 22, 2021. Tianjin Tanabe is a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC; Head Office: Chuo-ku, Osaka; President & Representative Director: Hiroaki Ueno).

China has about 120 million people with diabetes*, the largest in the world, and China accounts for approximately 30% of the total number of worldwide patients with diabetes. This proportion is expected to continue increasing. MTPC and Tianjin Tanabe signed a promotion agreement with another company in February 2019 but terminated the agreement due to environmental changes in the Chinese pharmaceutical market, and recently signed a new agreement with Suzuken (Shenzhen).

TENELIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor created by MTPC and is the first drug of its kind to originate from Japan. TENELIA has made it highly effective in lowering each of the postprandial blood glucose levels, as well as fasting blood glucose levels, with once-a-day administration. TENELIA needs no dose adjustments according to the levels of renal or hepatic dysfunction, so that TENELIA can be used to treat a wide range of patients with diabetes.

MTPC, which is the marketing authorization holder of TENELIA in China, obtained the approval from the Chinese authority on August 3, 2021. MTPC had filed through Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd., which is MTPC's R&D subsidiary in China.

China, which is the second largest pharmaceuticals market in the world, is an important market for MTPC and Suzuken (Shenzhen). Working together, both companies aim to attain better glycemic control for patients in China by providing a new option for the treatment of diabetes.

*2019. IDF : International Diabetes Federation

Mitsubishi Tanabe Pharma Corporation
Communication Crossroads Department

Media contacts: TEL: +81 6 6205 5119

A member of Mitsubishi Chemical Holdings Group.

KAITEKI Value for Tomorrow
Mitsubishi Chemical Holdings Group

<Reference>

About Tianjin Tanabe Seiyaku Co., Ltd.

Tianjin Tanabe Seiyaku Co., Ltd. was founded in Tianjin, China, in 1993 through joint financing from Tianjin Lisheng Pharmaceutical Co., Ltd. and MTPC. The company is engaged in the manufacture and sales of pharmaceuticals in China. As a core company of the MTPC group in China, the company seeks to contribute to medical needs in China through the manufacture and sales of high quality pharmaceuticals with the MTPC brand, particularly cardiovascular drugs, gastrointestinal drugs, and anti-allergic agents for patients in China.

About Suzuken (Shenzhen) Pharmaceutical Co., Ltd.

A joint venture between EPS China Group (Head Office: Suzhou, China) and Suzuken Co., Ltd. (Head Office: Nagoya, Aichi) which provides pharmaceutical sales, distribution, and mediation activities in China.

About EPS China Group

EPS China Group is a general term for a group of companies that the EPS group is focusing on developing the health industry in China. Aiming to be a specialist trading company in the healthcare industry that connects Japan and China, we engaged in the pharmaceutical business, medical device business, CRO business, investment business, etc. In October 2016, we received a capital injection from Suzuken Co., Ltd. which gave us a new opportunity to make significant strides. The pharmaceutical business of EPS China group is based on the Chinese market, building a value chain that includes pharmaceutical R&D, manufacturing, sales, and after-sales services, as well as aggressively introducing outstanding new drugs and generics from Japan, supporting subsequent development, clinical trials, and post-

launch sales in mainland China. In this way, we will expand our product line, pursue innovation in business models as well as products and services, and contribute to the development of the health industry.